These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38913024)

  • 1. Harness arsenic in medicine: current status of arsenicals and recent advances in drug delivery.
    Liu F; Deng Y; Wang A; Yang T; Ke H; Tang Y; Wu H; Chen H
    Expert Opin Drug Deliv; 2024 Jun; 21(6):867-880. PubMed ID: 38913024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.
    Chou WC; Dang CV
    Curr Opin Hematol; 2005 Jan; 12(1):1-6. PubMed ID: 15604884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia.
    Torka P; Al Ustwani O; Wetzler M; Wang ES; Griffiths EA
    Blood Rev; 2016 May; 30(3):201-11. PubMed ID: 26709030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
    Chen Z; Zhao WL; Shen ZX; Li JM; Chen SJ; Zhu J; Lallemand-Breittenbach V; Zhou J; Guillemin MC; Vitoux D; de Thé H
    Curr Top Microbiol Immunol; 2007; 313():129-44. PubMed ID: 17217042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases.
    Wang QQ; Jiang Y; Naranmandura H
    Metallomics; 2020 Mar; 12(3):326-336. PubMed ID: 32163072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia.
    Wang QQ; Hua HY; Naranmandura H; Zhu HH
    Toxicol Appl Pharmacol; 2020 Dec; 409():115299. PubMed ID: 33091440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.
    Slack JL; Waxman S; Tricot G; Tallman MS; Bloomfield CD
    Oncologist; 2002; 7 Suppl 1():1-13. PubMed ID: 11961204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
    Leu L; Mohassel L
    Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide.
    Guo M; Wang B; Liu S; Wang W; Gao C; Hu S; Fan S; Hai X; Zhou J
    Expert Rev Clin Pharmacol; 2019 Apr; 12(4):371-378. PubMed ID: 30795697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Will Arsenic Trioxide Benefit Treatment of Solid Tumor by Nano- Encapsulation?
    Fu X; Li YS; Zhao J; Yu LL; Luo RG; Liang QR; Tang Q
    Mini Rev Med Chem; 2020; 20(3):239-251. PubMed ID: 31760930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding the use of arsenic trioxide: leukemias and beyond.
    Chen Z; Chen GQ; Shen ZX; Sun GL; Tong JH; Wang ZY; Chen SJ
    Semin Hematol; 2002 Apr; 39(2 Suppl 1):22-6. PubMed ID: 12012319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies.
    Liu P; Han ZC
    Int J Hematol; 2003 Jul; 78(1):32-9. PubMed ID: 12894848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arsenic trioxide.
    Litzow MR
    Expert Opin Pharmacother; 2008 Jul; 9(10):1773-85. PubMed ID: 18570609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arsenic trioxide: applications, mechanisms of action, toxicity and rescue strategies to date.
    Yan M; Wang H; Wei R; Li W
    Arch Pharm Res; 2024 Mar; 47(3):249-271. PubMed ID: 38147202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia.
    Au WY; Tam S; Fong BM; Kwong YL
    Blood; 2006 Apr; 107(7):3012-3. PubMed ID: 16554490
    [No Abstract]   [Full Text] [Related]  

  • 16. Arsenic trioxide: insights into its evolution to an anticancer agent.
    Hoonjan M; Jadhav V; Bhatt P
    J Biol Inorg Chem; 2018 May; 23(3):313-329. PubMed ID: 29396610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors.
    Sönksen M; Kerl K; Bunzen H
    Med Res Rev; 2022 Jan; 42(1):374-398. PubMed ID: 34309879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
    Guo M; Zhou J; Fan S; Li L; Chen H; Lin L; Zhao Q; Wang X; Liu W; Wu Z; Hai X
    Expert Rev Clin Pharmacol; 2021 Apr; 14(4):503-512. PubMed ID: 33678104
    [No Abstract]   [Full Text] [Related]  

  • 19. In the war against solid tumors arsenic trioxide needs partners.
    Subbarayan PR; Ardalan B
    J Gastrointest Cancer; 2014 Sep; 45(3):363-71. PubMed ID: 24825822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The optimal dose of arsenic trioxide induced opposite efficacy in autophagy between K562 cells and their initiating cells to eradicate human myelogenous leukemia.
    Guo Z; Meng M; Geng S; Du Z; Zheng Y; Yao J; Li Z; Han G; Lin H; Du G
    J Ethnopharmacol; 2017 Jan; 196():29-38. PubMed ID: 27965050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.